Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of CP-690,550 as maintenance therapy in patients with Crohn's disease
2011-003622-27Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in Crohn's disease, sponsored by Pfizer. Primary endpoint: Safety endpoints. Started Feb 2012; status: terminated.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-003622-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003622-27.